Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
N. Steeghs
Institution:
The Netherlands Cancer Institute
Observed institution:
The Netherlands Cancer Institute
ORCID:
0000-0003-2989-2279
Observed ORCID:
0000-0003-2989-2279
OpenAlex ID:
A5035923195
OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer
2022
·
H. Borghaei
, L. Paz-Ares
, et al.
·
Journal of Thoracic Oncology
·
10
607O Interim results of a phase I study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors
2024
·
M. Oliva
, S. Ochsenreither
, et al.
·
Annals of Oncology
·
9
155P Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
2024
·
A.C. Chiang
, M.E. Olmedo Garcia
, et al.
·
Immuno-Oncology Technology
·
3
PDF
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors
2026
·
U. Lassen
, E.M.J. van Brummelen
, et al.
·
ESMO Open
·
2
PDF
147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer
2022
·
S. Champiat
, M. Boyer
, et al.
·
Immuno-Oncology Technology
·
2
363P Palbociclib exposure in relation to response and toxicity in patients with advanced breast cancer
2024
·
S.M. Buijs
, M.I. Mohmaed Ali
, et al.
·
Annals of Oncology
·
1
Expanding the use of approved drugs: The CPCT’s Drug Rediscovery Protocol (DRUP)
2017
·
D. van der Velden
, L. Hoes
, et al.
·
Annals of Oncology
·
1
PDF
3718RO Molecular response (MR) in KIT circulating tumor DNA (ctDNA) from StrateGIST 1: A phase 1/1b study of velzatinib (IDRX-42) in patients (pts) with advanced gastrointestinal stromal tumors (GIST)
2026
·
S. Bauer
, C. Serrano
, et al.
·
Annals of Oncology
100P Determinants of response to atezolizumab–bevacizumab (atezo–bev) in metastatic colorectal cancer (mCRC): Insights from the Motricolor CT3 trial
2026
·
C. Vaghi
, F.J. Ros Montana
, et al.
·
Annals of Oncology
PDF
206P Severe cognitive effects of avapritinib: Towards a mechanistic understanding
2026
·
J.M. Van Sabben
, H. Gelderblom
, et al.
·
ESMO rare cancers.
175P Retrospective analysis of 386 patients: An international study by the SDH-deficient GIST consortium
2026
·
E. Roets
, Y. Cheng
, et al.
·
ESMO rare cancers.
PDF
256P EXPAND-1, a phase I/II study of ANV600, a PD-1 targeted IL-2Rβγ agonist, in monotherapy and in combination with pembrolizumab, in advanced solid tumors
2025
·
M. Imbimbo
, E. Calvo
, et al.
·
Immuno-Oncology Technology
PDF
1549P EXPAND-1, a phase I/II study of ANV600, a PD-1 targeted IL-2R-βγ agonist, in monotherapy and in combination with pembrolizumab, in advanced solid tumors
2025
·
M. Imbimbo
, I. Korakis
, et al.
·
Annals of Oncology
956P Encouraging antitumor activity of PDL1V (PF-08046054) monotherapy, an ADC targeting PD-L1, correlates with antigen expression in patients with NSCLC
2025
·
M. Oliva Bernal
, A. Dowlati
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
13
Citation count:
28
H-index:
3
I10-index:
1
Year
Topic
Type